Interferon-α for the treatment of elderly patients with chronic myeloid leukaemia

Leukemia Research

Volumn 22, Issue 10, 1998, Pages 881-886

  Hilbe, Wolfgang ^a   Apfelbeck, Ute ^a   Fridrik, Michael ^a   Bernhart, Marianne ^a   Niessner, Herwig ^a   Abbrederis, Klaus ^a   Michlmayr, Gerhard ^a   Pont, Jörg ^a   Linkesch, Werner ^a   Hausmaninger, Hubert ^a   Arneitz, Klaus ^a   Baldinger, Christian ^a   Duba, Christoph ^a   Eisterer, Wolfgang ^a   Greil, Richard ^a   Konwalinka, Günther ^a   Niederwieser, Dietger ^a   Gastl, Günther ^a   Thaler, Josef ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Age; CML; Interferon ; LD ara C; Side effects

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; CYTARABINE; HYDROXYUREA;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BONE PAIN; CANCER STAGING; CANCER SURVIVAL; CHILD; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; DEPRESSION; DIARRHEA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; KIDNEY DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0032191474     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00064-2     Document Type: Article

References (15)

1. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queiber W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griebhammer M, Bergmann L, Essers U, Falge C, Queiber U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Kabisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges F-J, Schid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow PV, Prümmer O, Thiele J, Buhr T, Carbonell F, Ansari H Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 84:1994;4064.
2. Tura S, Baccarani M, Zuffa E, Russo D, Fanin R, Zaccaria A, Fiacchini M Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 330:1994;820.
3. Allan NC, Richards SM, Shepherd PCA UK Medical Research Council randomised, multicentre trial of interferon-α 1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet. 345:1995;1392.
4. Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Sill H, Lang A, Falk M, Duba C, Utermann G, Kuhr T, Aulitzky W, Huber C Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long term results of a multicenter phase-II study. Ann Hematol. 72:1996;349.
5. Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, Pont J, Bernhart M, Stöger M, Niessner H, Abbrederis K, Geissler D, Hausmaninger R, Lin W, Ludwig H, Lang A, Duba C, Fluckinger T, Greil R, Grünewald K, Konwalinka G, Niederwieser D, Fridrik MA Interferon-alpha-2c and LD ara-C for the treatment of patients with CML: preliminary results of the Austrian multicenter phase II study. Leuk Res. 21:1997;75.
6. Miller AB, Hoogstraten B, Straquet M, Winkler A Reporting results of cancer treatment. Cancer. 47:1981;207.
7. Yunis JJ New chromosome techniques in the study of human neoplasia. Hum Pathol. 12:1981;540.
8. a in chronic myelogenous leukemia. N Engl J Med. 314:1986;1065.
9. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood. 63:1984;789.
10. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med. 122:1995;254.
11. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Hirashima K, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Yamada K A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 86:1995;906.
12. Baranovsky A., Myers MH Cancer incidence and survival in patients 65 years of age and older. CA Cancer J Clin. 36:1986;26.
13. Brincker H Population-based age- and sex-specific incidence in the 4 main types of leukemia. Scan J Haematol. 29:1982;241.
14. Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M Results of interferon-alpha therapy in patients with chronic myeloid leukemia 60 years of age and older. Am J Med. 100:1996;452.
15. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 337:1997;223.